BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 11931669)

  • 1. Fusion of two distinct peptide exosite inhibitors of Factor VIIa.
    Roberge M; Peek M; Kirchhofer D; Dennis MS; Lazarus RA
    Biochem J; 2002 Apr; 363(Pt 2):387-93. PubMed ID: 11931669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel exosite on coagulation factor VIIa and its molecular interactions with a new class of peptide inhibitors.
    Roberge M; Santell L; Dennis MS; Eigenbrot C; Dwyer MA; Lazarus RA
    Biochemistry; 2001 Aug; 40(32):9522-31. PubMed ID: 11583151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection and characterization of a new class of peptide exosite inhibitors of coagulation factor VIIa.
    Dennis MS; Roberge M; Quan C; Lazarus RA
    Biochemistry; 2001 Aug; 40(32):9513-21. PubMed ID: 11583150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering exosite peptides for complete inhibition of factor VIIa using a protease switch with substrate phage.
    Maun HR; Eigenbrot C; Lazarus RA
    J Biol Chem; 2003 Jun; 278(24):21823-30. PubMed ID: 12657647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide exosite inhibitors of factor VIIa as anticoagulants.
    Dennis MS; Eigenbrot C; Skelton NJ; Ultsch MH; Santell L; Dwyer MA; O'Connell MP; Lazarus RA
    Nature; 2000 Mar; 404(6777):465-70. PubMed ID: 10761907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of Tissue Factor. Factor VIIa for anticoagulant therapy.
    Lazarus RA; Olivero AG; Eigenbrot C; Kirchhofer D
    Curr Med Chem; 2004 Sep; 11(17):2275-90. PubMed ID: 15379712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macromolecular substrate affinity for free factor VIIa is independent of a buried protease domain N-terminus.
    Persson E
    Biochem Biophys Res Commun; 2006 Mar; 341(1):28-32. PubMed ID: 16406236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The quest for Factor VIIa exosite inhibitors.
    Amour A; Hutchinson J; Ruiz Avendaño AM; Ratcliffe S; Alvarez E; Martin J; Toomey JR; Senger S; Wolfendale M; Mooney C
    Biochem Soc Trans; 2007 Jun; 35(Pt 3):555-8. PubMed ID: 17511650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Four loops of the catalytic domain of factor viia mediate the effect of the first EGF-like domain substitution on factor viia catalytic activity.
    Jin J; Perera L; Stafford D; Pedersen L
    J Mol Biol; 2001 Apr; 307(5):1503-17. PubMed ID: 11292356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptides corresponding to the second epidermal growth factor-like domain of human blood coagulation factor VII: synthesis, folding and biological activity.
    Husbyn M; Orning L; Sakariassen KS; Fischer PM
    J Pept Res; 1997 Dec; 50(6):475-82. PubMed ID: 9440049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The tissue factor/factor VIIa/factor Xa complex: a model built by docking and site-directed mutagenesis.
    Norledge BV; Petrovan RJ; Ruf W; Olson AJ
    Proteins; 2003 Nov; 53(3):640-8. PubMed ID: 14579355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors of factor VIIa affect the interface between the protease domain and tissue factor.
    Carlsson K; Persson E; Carlsson U; Svensson M
    Biochem Biophys Res Commun; 2006 Oct; 349(3):1111-6. PubMed ID: 16970919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue Factor Residues That Modulate Magnesium-Dependent Rate Enhancements of the Tissue Factor/Factor VIIa Complex.
    Gajsiewicz JM; Nuzzio KM; Rienstra CM; Morrissey JH
    Biochemistry; 2015 Aug; 54(30):4665-71. PubMed ID: 26169722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based design of P3 moieties in the peptide mimetic factor VIIa inhibitor.
    Kadono S; Sakamoto A; Kikuchi Y; Oh-eda M; Yabuta N; Yoshihashi K; Kitazawa T; Suzuki T; Koga T; Hattori K; Shiraishi T; Haramura M; Kodama H; Ono Y; Esaki T; Sato H; Watanabe Y; Itoh S; Ohta M; Kozono T
    Biochem Biophys Res Commun; 2005 Feb; 327(2):589-96. PubMed ID: 15629154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel soluble tissue factor variant with an altered factor VIIa binding interface.
    Lee GF; Kelley RF
    J Biol Chem; 1998 Feb; 273(7):4149-54. PubMed ID: 9461610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolutionary Adaptations in Pseudonaja Textilis Venom Factor X Induce Zymogen Activity and Resistance to the Intrinsic Tenase Complex.
    Schreuder M; Poenou G; Strijbis VJF; Cheung KL; Reitsma PH; Bos MHA
    Thromb Haemost; 2020 Nov; 120(11):1512-1523. PubMed ID: 32820486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two independent binding sites on monolayers of human endothelial cells are responsible for interaction with coagulation factor VII and factor VIIa.
    Reuning U; Preissner KT; Müller-Berghaus G
    Thromb Haemost; 1993 Feb; 69(2):197-204. PubMed ID: 8456434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor.
    ten Cate H; Bauer KA; Levi M; Edgington TS; Sublett RD; Barzegar S; Kass BL; Rosenberg RD
    J Clin Invest; 1993 Sep; 92(3):1207-12. PubMed ID: 8376580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding of Zn2+ to a Ca2+ loop allosterically attenuates the activity of factor VIIa and reduces its affinity for tissue factor.
    Petersen LC; Olsen OH; Nielsen LS; Freskgård PO; Persson E
    Protein Sci; 2000 May; 9(5):859-66. PubMed ID: 10850795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of the factor X activation peptide: a deletion mutagenesis approach.
    Rudolph AE; Mullane MP; Porche-Sorbet R; Daust HA; Miletich JP
    Thromb Haemost; 2002 Nov; 88(5):756-62. PubMed ID: 12428090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.